NSD2 is a conserved driver of metastatic prostate cancer progression-Reference-Cited by-同舟云学术

NSD2 is a conserved driver of metastatic prostate cancer progression

Published:2018-12 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Aytes Alvaro,Giacobbe Arianna,Mitrofanova Antonina,Ruggero Katia,Cyrta Joanna,Arriaga Juan,Palomero Luis,Farran-Matas Sonia,Rubin Mark A.,Shen Michael M.^ORCID,Califano Andrea,Abate-Shen Cory

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-07511-4.pdf

Reference63 articles.

1. Lambert, A. W., Pattabiraman, D. R. & Weinberg, R. A. Emerging biological principles of metastasis. Cell 168, 670–691 (2017).

2. Vanharanta, S. & Massague, J. Origins of metastatic traits. Cancer Cell. 24, 410–421 (2013).

3. Bos, P. D., Nguyen, D. X. & Massague, J. Modeling metastasis in the mouse. Curr. Opin. Pharmacol. 10, 571–577 (2010).

4. Maddipati, R. & Stanger, B. Z. Pancreatic cancer metastases harbor evidence of polyclonality. Cancer Discov. 5, 1086–1097 (2015).

5. Aytes, A. et al. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer. Proc. Natl Acad. Sci. USA 110, E3506–E3515 (2013).

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis;Nature Genetics;2024-09-09

2. Recent advances in targeting histone H3 lysine 36 methyltransferases for cancer therapy;European Journal of Medicinal Chemistry;2024-08

3. Discovery of a Highly Potent Lysine Methyltransferases G9a/NSD2 Dual Inhibitor to Treat Solid Tumors;Journal of Medicinal Chemistry;2024-07-15

4. Multilevel Regulation of NF‐κB Signaling by NSD2 Suppresses Kras‐Driven Pancreatic Tumorigenesis;Advanced Science;2024-06-18

5. Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader;Journal of Medicinal Chemistry;2024-04-30